An experimental drug has been found to be effective at relieving neuropathic pain caused by shingles, and may also be useful in treating other types of neuropathy caused by diabetes, HIV and chemotherapy.
Many drugs now used to treat neuropathic pain, such as Neurontin and Lyrica, often don’t work or have unpleasant side effects.
The new drug, called EMA401, was developed by Spinifex Pharmaceuticals, an Australian biotechnology company.
Shingles is caused when a dormant viral infection of a nerve is reactivated, resulting in a painful rash. In most cases, the rash lasts a few weeks, but in some cases the virus causes permanent nerve damage that results in a chronic neuropathic pain called post-herpetic neuralgia. Around one in 10 people with shingles has post-herpetic neuralgia. Once established, it usually lasts a lifetime.
You can read the entire article at National Pain Report.